Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cell Death Dis. 2021 Mar 12;12(3):266. doi: 10.1038/s41419-021-03553-7.
Hepatocellular carcinoma (HCC) is a highly lethal malignancy characterized by poor prognosis and a low 5-year survival rate. Drug treatment is proving to be effective in anti-HCC. However, only a small number of HCC patients exhibit sensitive responses, and drug resistance occurs frequently in advanced patients. Autophagy, an evolutionary process responsible for the degradation of cellular substances, is closely associated with the acquisition and maintenance of drug resistance for HCC. This review focuses on autophagic proteins and explores the intricate relationship between autophagy and cancer stem cells, tumor-derived exosomes, and noncoding RNA. Clinical trials involved in autophagy inhibition combined with anticancer drugs are also concerned.
肝细胞癌（HCC）是一种高度致命的恶性肿瘤，其预后不良，5 年生存率低。药物治疗在抗 HCC 方面已被证明是有效的。然而，只有少数 HCC 患者表现出敏感反应，晚期患者经常发生耐药性。自噬是一种负责细胞物质降解的进化过程，与 HCC 获得和维持耐药性密切相关。本综述重点介绍自噬蛋白，并探讨自噬与癌症干细胞、肿瘤来源的外泌体和非编码 RNA 之间的复杂关系。还关注了自噬抑制与抗癌药物联合的临床试验。
